ymabs.com - Multiplikator EV/Sales YMAB

The EV/Sales ratio provided by the GURU.Markets platform demonstrates the market resilience of Y-mAbs Therapeutics (YMAB). The figure expresses the current value of the metric, confirming high margins driven by monopoly sales of the drug Danyelza. Its status as a scientific leader in immuno-oncology ensures the company maintains physician trust. The business is currently scaling its portfolio of targeted antibodies and expanding distribution across US hospitals.
Rincian metrik keuangan lan pasar Y-mAbs Therapeutics, Inc. (YMAB)

For Y-mAbs Therapeutics (YMAB), the EV/Sales multiple reflects the enterprise value relative to generated revenue. This ratio eliminates the impact of capital structure, allowing for an assessment of the actual asset value per unit of sales. The high margins of Danyelza within the narrow neuroblastoma niche make this metric sensitive to demand dynamics. A stable market moat protects the company from sharp valuation swings, while low indicator values may signal liquidity risks.